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Abstract
Recurrent pregnancy loss (RPL) affects 0.8–1.4% of couples, and this preva-
lence increases with aging. However, etiology is commonly unknown, and most 
therapies are not supported by strong evidence. There are many examinations that 
investigate causes of RPL: hormonal status, spermatozoa morphology and DNA 
fragmentation, immunologic status, uterine assessment, thrombophilia, and others. 
Recently different types of treatment have emerged, most lacking good evidence. 
As for example, we may mention the use of anticoagulants, aspirin, corticosteroids, 
progesterone, and antioxidants and psychological support. It is argued that some 
procedures such as preimplantation genetic testing for aneuploidy and intracyto-
plasmic morphologically selected sperm injection would impact on the outcomes 
and help RPL management. This chapter will discuss the current evidence concern-
ing examinations and treatments that would improve the outcomes in patients with 
RPL, with recommended practice.
Keywords: recurrent pregnancy loss, recurrent miscarriage, in vitro fertilization, 
infertility, preimplantation genetic testing for aneuploidy, thrombophilia, sperm DNA 
fragmentation, natural killer cells, reproductive techniques, maternal KIR, paternal 
HLA-C
Keypoints
The practice of physical activity, healthy eating, quitting smoking, and reduction of alcohol consumption 
are factors that interfere in the reproductive outcomes. Medical understanding and ability to listen to patients 
about their obstetric past are fundamentally important for the treatment.
The genetic investigation is controversial and consists of chromosomal evaluation of the conception 
products and the couple’s karyotype. The goal is to identify the etiology of the loss and may be useful for future 
guidance of the couple. There is no consensus on performing IVF-PGT, and this option should be discussed 
case by case. In extreme cases IVF using donated gametes may be the last option., 
Patients with RPL without other risk factors for thrombosis should not be screened for inherited 
thrombophilias, and those with positive screening have no benefit from available treatment. The only 
thrombophilia that should be routinely investigated for early miscarriage is APS. The recommended treatment 
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1. Introduction
Recurrent pregnancy loss (RPL) is defined by two or more losses with gesta-
tional age less than 20–24 weeks [1, 2]. Its prevalence varies between 0.8 and 1.4% 
considering only patients who have had a clinical pregnancy [2]. The pathogenesis 
is multifactorial, and in only 50% of the cases, the causal factor can be identified: 
immunological, endocrine, genetic, metabolic, and anatomical, among others [3]. 
The identification of etiology is not always possible, and recurrence of miscar-
riage seems to influence negatively the couple’s psychological profile [2]. Thus, 
the understanding of diagnostic methods that can identify etiological factors and 
treatments that can improve the outcome is fundamental for the follow-up of 
couples with RPL.
2. Risk factors
Some personal factors such as lifestyle and even environmental exposure 
may be associated with obstetric complications and gestational loss. Advanced 
maternal age is one of the best-established risk factors in the literature for RPL [2]. 
Approximately 50–70% of early gestational losses are associated with chromosomal 
abnormalities, and their incidence increases with maternal age, reaching 50% 
in women over 40 years [3]. The European Society of Human Reproduction and 
Embryology (ESHRE) recommends that women should be informed of the highest 
risk of miscarriage after age 40 [2].
Obesity also has a major impact on women’s reproductive health. High body 
mass index (BMI) is associated with worse outcomes in infertility treatments and 
a higher incidence of gestational loss [4]. One study with obese women showed a 
higher frequency of euploid miscarriages than nonobese women (58% vs. 37%) [5]. 
is the use of low-dose AAS preconception and LMWH in a prophylactic dose initiated when diagnosing 
pregnancy., 
Screening immunological factors for patients with RPL is not recommended. There is also no 
recommendation to use venous immunoglobulin or corticosteroids empirically. Only antinuclear antibody can 
be ordered for prognostic purposes, according to ESHRE., 
Screening for congenital uterine anomalies is part of the investigation of women with a history of 
RPL. Nuclear magnetic resonance is the gold standard for diagnosis. The only finding that can be surgically 
corrected and prognosis improved is the septate uterus., 
The diagnosis of cervical incompetence is based on clinical history. The classic treatment is transvaginal 
cerclage between 12 and 16 weeks after first trimester morphological ultrasound., 
Patients with RPL should undergo through endometrial cavity evaluation. The gold standard is 
hysteroscopy. Although there is limited evidence linking submucosal fibroids, endometrial polyps, and 
synechiae with RPL, surgical correction in patients with RPL without other identifiable factors is suggested., 
There are no research and treatment benefits for PCOS patients and their associated endocrine disorders. 
Thyroid evaluation should be performed with serum TSH and anti-TPO, and clinical hypothyroidism 
should be treated. For prolactin, the test is not indicated in the absence of signs of hyperprolactinemia, but 
if this condition is diagnosed, treatment is indicated. Vitamin D test is not routinely recommended, but the 
preconception counseling in women with RPL may include prophylactic vitamin D supplementation due to 
the high prevalence of hypovitaminosis D in this population., 
The relationship of chronic endometritis with RPL is unclear. The current gold standard for the diagnosis 
of chronic endometritis is the pathological anatomy of immunohistochemically endometrial biopsy for the 
CD138 marker. A therapeutic option would be the use of doxycycline alone or in combination with other 
antibiotics., 
For male factor, measurement of spermatic DNA fragmentation index and Kruger morphology would be 
indicated. The use of antioxidants is a clinical treatment that can improve DNA fragmentation. In the presence 
of ICSI indication associated with increased spermatic DNA fragmentation, the use of testicular, IMSI, or 
PICSI sperm can be considered.
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This is probably due to the association of obesity with several endocrine disorders, 
such as diabetes, hypothyroidism, and polycystic ovary syndrome and possibly 
endometrial changes [5]. The Royal College of Obstetricians and Gynecologists 
(RCOG) recommends prepregnancy weight loss due to the associated increased risk 
of miscarriage, stillbirth, preeclampsia, diabetes, and postpartum hemorrhages 
[6]. The practice of regular physical activity presents improvement in the obstetric 
outcome; however, there are no studies investigating the impact of exercise in 
patients with RPL [2].
Smoking seems to be related to defects in trophoblastic function, thus increas-
ing the risk of gestational loss, in addition to poor obstetric prognosis [2]. Assisted 
reproduction societies recommend quitting smoking because of the negative impact 
on the chances of a live birth [2, 3]. Several studies have shown that drinking 
alcohol during pregnancy also increases the risk of gestational loss [2]. Although 
further studies are needed to establish if there is any safe dose for drinking in 
pregnancy, there are recommendations for couples with RPL not to drink alcohol.
Caffeine abuse can also affect fertility as well as be a risk factor for gestational 
losses. Ingestion of high caffeine levels (500 mg per day or > 5 cups per day) is 
associated with decreased fertility [7]. During pregnancy, drinking between 200 
and 300 mg/day (2–3 cups) may increase the risk of miscarriage [3]. Thus, it seems 
sensible to guide this population to reduce caffeine consumption.
Few studies assess environmental exposure as a risk factor for RPL, one of 
which suggests that exposure to heavy metals and lack of micronutrients may cause 
gestational loss [8]. Another study suggests that ingestion of high concentrations of 
organochlorine pesticides may be associated with RPL [9].
It has been suggested in the past that stress could be associated with worsening 
the reproductive outcomes. There is a higher prevalence of depression in patients 
with RPL [10], but it is not known if this picture is not the cause or effect of RPL 
[2]. The American Society for Reproductive Medicine (ASRM) advises psychologi-
cal support for these women who are more prone to feelings of grief, sadness, 
depression, anxiety, and guilt [3].
3. Genetic factors
The human conception is a vulnerable event—a large proportion of all concep-
tions are cytogenetically abnormal, and most of such pregnancies evolve to abor-
tion. In couples with RPL, research can be divided into two main categories: genetic 
analysis of products of conception and parental genetic analysis.
3.1 Genetic analysis of products of conception
Studies in which products of conception were analyzed showed that genetic 
alterations, mainly aneuploidies, contribute to a significant portion of the 
causes of gestational losses, accounting for 50% of recurrent losses [11]. Despite 
the importance of genetic alterations as causes of miscarriage, there is still no 
consensus as to whether routine evaluation of pregnancy tissue should be per-
formed. ASRM does not recommend genetic evaluation of conception products 
[3]. ESHRE, in turn, suggests that this analysis should not be done routinely but 
that it may be promoted for the purpose of clarifying the etiological factor and to 
assist in deciding whether further investigation or treatment is needed [2]. Other 
studies and guidelines, however, have proposed new algorithms in which the 
assessment of gestational repetition losses should be initiated with chromosome 
testing in conception products [12].
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New chromosomal tests such as the chromosomal microarray analysis (CMA) 
have the potential to reduce costs since, in the presence of altered examination, 
costly and unnecessary evaluations will not be employed [13]. In addition, when a 
cause is identified, the tendency is to reduce the use of empirical treatments that 
have no scientific evidence [13]. Research has shown that in couples with previous 
embryonic aneuploidy, the likelihood of a child’s birth during subsequent pregnan-
cies was higher than patients with prior normal karyotype of conception products 
(71% vs. 44%) [14].
The suffering that the couple goes through experiencing abortion episodes 
without knowing the etiological factor can by itself justify the investigation of the 
existence of genetic alterations as a cause of the events.
3.2 Parental genetic analysis
In about 5% of all couples suffering two or more fetal losses, one partner 
carries a balanced chromosomal rearrangement, which represents approximately 
eightfold increase compared to the general population [15]. Guiding this couple 
for genetic counseling is important, as the likelihood of a healthy child born will 
depend on the type of rearrangement found and the chromosomes involved—for 
example, gestational losses are more present in carriers of balanced translocations 
and inversions than in carriers of Robertsonian translocations [16]. Even with one 
spouse carrying a chromosomal rearrangement, the cumulative rate of live birth, 
even in natural conception, is significant—63.4% despite the increased risk for 
miscarriage [17].
As for the existing guidelines regarding parental cytogenetic investigation, 
ESHRE determines that such assessment should not be performed routinely, but in 
specific cases after individual risk assessment [2]. ASRM, however, recommends 
routine parental karyotyping as information obtained may assist in counseling on 
the prognosis of future pregnancies, including guidance for performing preimplan-
tation genetic testing (PGT), amniocentesis, or chorionic villus analysis [3].
Couples with structural cytogenetic changes have an increased number of 
gametes with chromosomal imbalances, so it would be expected that the implan-
tation of embryos selected by PGT increases the rate of live births. However, in 
spouses carrying chromosomal rearrangement with RPL, the rate of live births, 
time to subsequent conception, and miscarriage rates were similar in both naturally 
conceived and in vitro fertilization associated with preimplantation diagnosis (IVF-
PGT) [18]. Other papers showed discordant results. Similar live birth rate and time 
to new pregnancy were reported; however, the miscarriage rate was significantly 
lower in the IVF-PGT group [19]. Thus, there is no consensus showing the benefit 
of such strategy in this population, and no randomized controlled trials have been 
conducted to this date to validate possible benefits.
4. Thrombophilias
Thrombophilias are inherited and/or acquired conditions that predispose 
individuals to thrombosis, with varied prevalence in the general population [20]. 
The most common hereditary thrombophilias are methylenetetrahydrofolate 
reductase (MTHFR) gene polymorphism 4–16%, factor V Leiden mutation 1691G 
→ A (heterozygote, 1–15%; homozygote, <1%), prothrombin mutation 20210G → A 
(heterozygote, 2–5%; homozygote, <1%), antithrombin deficiency (0.02%), protein 
C deficiency (0.2–0.4%), protein S deficiency (0.03–0.13%) [21], and serpin gene 
polymorphism. On the other hand, acquired thrombophilia is mainly represented 
5Recurrent Pregnancy Loss: Investigations and Interventions
DOI: http://dx.doi.org/10.5772/intechopen.89590
by the antiphospholipid antibody syndrome (APS) 2% [20]. Successful pregnancy 
requires an adequate endovascular implantation and remodeling measured by 
trophoblast, and these prothrombotic conditions would be the target of investiga-
tion and intervention with anticoagulant therapy to prevent miscarriage [21].
4.1 Inherited thrombophilias
The screening of inherited thrombophilias even in patients with a thrombosis 
context is still questioned [2]. The factor V Leiden mutation (1691G→ A) and the 
prothrombin mutation (20210G→ A) were related to recurrent miscarriage [22]; 
however, the lack of evidence that the treatment changes the gestational outcome 
leads to questioning the relevance of investigating such mutations. Other throm-
bophilias, such as protein C deficiency, protein S deficiency, and antithrombin 
deficiency, although associated with thromboembolic event, were not associated 
with RPL [2, 3, 20, 22]. MTHFR gene polymorphisms are no longer considered risk 
factors for thrombophilias [2].
The association between RPL and inherited thrombophilias is weak or absent 
[2]. Thus, thrombophilic screening should be restricted to patients with family 
history of thrombophilias or previous thrombotic event [1, 2]. There is no recom-
mendation to screen inherited thrombophilias in patients with RPL without other 
risk factors [1, 2, 21, 23]. Screening tests may be influenced by physiological/
pathophysiological changes in the pregnancy-puerperal period, thrombotic event, 
or use of anticoagulants [21]. It should be performed within 6 weeks or more after 
delivery, miscarriage, or thrombotic event or early if necessary [2, 21].
The use of anticoagulant therapy with low-molecular-weight heparin and/or 
aspirin has no benefit in preventing early (<10 weeks) or late (≥10 weeks) RPL 
[24]. Thus, ineffectiveness of the treatment, the risk exposure, and the increased 
cost do not justify treatment with anticoagulants in patients with inherited throm-
bophilias and RPL without other risk factors for thrombosis [2, 20].
4.2 Acquired thrombophilias
APS is indicated in patients with RPL, as well as in patients with adverse gesta-
tional outcome or episode of thrombosis without apparent cause [25]. The diagnosis 
of APS is based on the combination of at least one clinical criterion, which includes 
thrombotic events and/or gestational morbidity, and a laboratory criterion, which 
includes three antibodies: lupus anticoagulant, anticardiolipin, and anti-β2 glyco-
protein 1 (anti-β2GP1) [25].
In the cases of late gestational loss, lupus anticoagulant was more closely related 
to RPL than any of the other antibodies [26, 27]. Anticardiolipin (IgG and IgM) 
has been associated with early and late gestational loss [26, 27]. The relationship 
between anti-β2GP1 and late gestational loss seems to be controversial [26, 27]. 
ESHRE recommends for patients with two losses, consecutive or not, to conduct a 
research for lupus anticoagulant antibodies and anticardiolipin, and the research 
should consider anti-β2GP1.
The use of combined therapy, low-molecular-weight heparin at prophylac-
tic dose, and low aspirin dose (75–100 mg/day) increases the live birth rate in 
patients with APS and RPL from 10% to 70–80% [28]. In treatment failure, the 
use of heparin in therapeutic dose may be used, although there is no benefit 
evidence [28]. Other treatment regimens with limited evidence are the use of 
hydroxychloroquine or low dose of prednisolone in the first trimester [28]. The 
use of immunoglobulin is questioned because studies are limited and show no 
increase in live birth rate [28].
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5. Immunological factors
To be successful in pregnancy, the maternal organism needs to undergo immu-
nological changes that allow and assist in the trophoblastic invasion of the embryo. 
During pregnancy, the maternal immune system faces a dilemma: it needs to 
protect the mother against infection while accepting the semi-allogeneic fetus [29]. 
Leukocytes are important components of the endometrium, and their concentra-
tion increases in the middle of the secretory phase in which embryonic implantation 
is expected and continues to increase during early pregnancy [30]. The proges-
terone plays a key role in this balance by creating an appropriate environment for 
embryonic implantation and development [28]. This change in maternal endome-
trial immunology becomes essential for early pregnancy implantation and success. 
Changes in this phase can lead to implantation failure, miscarriage, and other 
unfavorable obstetric outcomes such as preeclampsia.
5.1 Natural killer (NK) cell
The uterine natural killer (uNK) cells are the most commonly found leukocytes 
in the maternal endometrium. Two phenotypes are observed—CD56bright and 
CD16dim—unlike peripheral blood where CD56dim and CD16+ are the largest 
population [31]. There is a variability of their own concentration during the men-
strual cycle. There are a significant increase of NK cells in the endometrium 6 to 
7 days after the peak of luteinizing hormone (LH), which persists throughout the 
early pregnancy. This increase suggests an important role of these cells in embry-
onic implantation, but the exact function is still unknown [30].
5.1.1 Killer immunoglobulin-like receptors (KIR)
The placental formation is regulated by the interaction between the killer 
immunoglobulin-like receptors (KIR) and the surface human leukocyte antigens 
on the embryo trophoblastic cells (HLA-C). The embryo presents maternal and 
paternal HLA-C, and both haplotypes are presented to NK cells that, in turn, will 
recognize the human leukocyte antigen (HLA) foreign to their organism. There are 
two types of HLA-C: C1 and C2 which are a strong ligand to the receptor. On the 
other hand, there are two KIR haplotypes: A, which is inhibitory, and B, which is 
stimulating. The receptors can then be AA, AB, or BB. The presence of haplotype 
B confers pregnancy protection, and its absence (in the cases of KIR AA) increases 
the risk of gestational complications.
Studies have shown that when maternal KIR is homozygous for haplotype A 
(KIR AA), there is an increased risk of gestational complications if the embryo 
carries paternal HLA-C2 [32, 33]. In the future, these studies may be applicable to 
couples who will undergo IVF. Further studies on the subject are still needed, and 
these tests are not quoted to be traced by societal guidelines.
5.2 Macrophages
The macrophages represent 20–30% of leukocytes in the maternal endo-
metrium and are the second largest group behind only NK cells. Macrophages 
differ in specific phenotypes to perform different biological functions and can be 
divided into two subgroups: M1 and M2. M1 macrophages are pro-inflammatory 
and antimicrobial, whereas M2 have anti-inflammatory function [34]. For 
maternal and fetal tolerance to occur, more macrophages are polarized into the 
M2 subtype with immunosuppressive properties necessary for normal pregnancy 
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to occur [35]. When polarization of these cells does not occur correctly favoring 
the M1 subgroup, improper remodeling of the arteries and trophoblastic invasion 
occurs, leading to a higher incidence of miscarriage, preeclampsia, and prema-
ture birth [35].
5.3 Regulatory T cells
Regulatory T cells (Treg) are a subpopulation of T cells that play an essential 
role in maintaining maternal immune tolerance. These cells are activated by the 
presented antigens and from that moment secrete cytokines that will determine 
the differentiation of T cell subtypes, thus modulating the immune response. 
Depending on the released cytokines, T cells may differentiate into Treg cells 
expressing interleukin 10 and transforming growth factor β (TGFβ) responsible for 
immune tolerance to the conceptus or Th17 expressing interleukins 17, 21, and 22 
responsible for autoimmunity and gestational loss. Treg cells will then regulate the 
response to foreign antigens when an aggressive response is not appropriate, having 
the ability to inhibit type 1 helper (Th1) cells. There is evidence in the cases of 
recurrent gestational loss of unknown cause to increase Th17 and to decrease Treg 
cells, leading to an inadequate immune response [29].
6. Anatomical factors
Uterine anatomical abnormalities, both acquired and congenital, are associ-
ated with RPL. It is estimated that uterine factors may account for 10–50% of 
RPL [36].
6.1 Congenital uterine anomalies
6.1.1 Congenital Müllerian duct anomalies
Congenital uterine anomalies (CUA) arise from defects along any stage of 
the Müller duct development process during embryonic development, whether 
in formation, fusion, or reabsorption. The frequency of CUA has been reported 
between 1.8 and 37.6% in women with a history of RLP. This variation is due to the 
different diagnostic methods and criteria [37]. Septate uterus is the most common 
anomaly in patients with a history of abortion. Arched, septate, and bicornuate 
uterus account for up to 85% of anomalies [38].
In a meta-analysis it was observed that patients with septate or bicornuate 
uterus had a higher rate of miscarriage in the first and second trimester than a 
control group [39]. In another meta-analysis, the evaluation of uterine abnormality 
subtypes resulting from fusion defect showed that women with unicornuate and 
bicornuate uterus were more likely to have first-trimester abortion compared to 
those with normal uterus [40].
ASRM’s original classification system for congenital uterine anomalies has been 
modified and adapted and is still the most widely used today [41]. In 2012, ESHRE/
ESGE published a classification system aiming to replace the subjective criteria of 
ASRM’s classification by the absolute morphometric criteria [42]. Based on this 
classification, up to 58% of women previously diagnosed with ASRM arched uterus 
would be reclassified as having a partial septate uterus. There would be a potential 
increase in the number of surgical corrections for uterine anomaly, without any 
evidence showing that such a practice would be beneficial [43]. Therefore, caution 
is needed in using this new classification until further prospective, randomized, 
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controlled, long-term studies are available to associate the severity of uterine cavity 
distortion with reproductive results.
Given the suspicion, it is necessary to use diagnostic methods that can clearly 
visualize the external contour of the uterus and endometrial cavity. Both 3D ultra-
sound with inversion mode (3D US) and magnetic resonance imaging (MRI) can be 
used for this purpose, with good correlation between them [44]. The disadvantages 
of MRI are that it is a more expensive and less available method than ultrasound.
In a comparative study of different diagnostic modalities, higher accuracy of 3D 
hysterosonography compared with 3D US and 2D hysterosonography was observed, 
although the differences between these imaging techniques did not reach statistical 
significance in the diagnosis of arched, bicornuate, and septate uterus [45].
The uterine septum is the most common abnormality related to RPL [36] and 
the only remediable one. Despite the lack of randomized and controlled prospec-
tive studies comparing surgery to expectant treatment, limited studies indicate that 
hysteroscopy septal resection is associated with a reduction in subsequent abortion 
rates and an improvement in live birth rates in patients with RPL [41]. After hystero-
scopic resection of the septum, an interval of at least 2 months should be expected 
for complete healing of the endometrial cavity before a new pregnancy [41].
In general, CUA may be associated with renal abnormalities in approximately 
11–30% of individuals [41]; for this reason there is a need for urinary tract investi-
gation in these cases.
6.1.2 Cervical incompetence
Cervical incompetence (CI) is the inability of the cervix to keep the intrauterine 
fetus in the absence of uterine contractions or labor (painless cervical dilatation) due 
to a functional or structural defect. It is a recognized cause of RPL in the second tri-
mester, but the true incidence is unknown, as the diagnosis is essentially clinical [2].
The CI can be congenital or acquired. The most common congenital cause is a 
defect in the embryological development of the Müllerian ducts. The most common 
acquired cause is cervical trauma, such as cervical lacerations during childbirth, 
cervical conization, or forced cervical dilation during uterine procedures [46].
The diagnosis is usually based on a history of miscarriage in the second trimes-
ter, preceded by spontaneous rupture of membranes or painless cervical dilation. 
There are currently no objective tests capable of identifying women with cervical 
weakness in the nonpregnant state [2].
Transvaginal ultrasound may be used in at-risk patients during pregnancy. 
CI might be suspected when there is a short cervical length, less than or equal to 
25 mm, or funneling, protrusion of the membrane into a dilated internal orifice but 
with closed external orifice [46].
Many surgical and nonsurgical modalities have been proposed to treat cervical 
incompetence. Among nonsurgical activities, restriction of activities and bed rest were 
not effective in the treatment of cervical incompetence. Its isolated use is discouraged. 
The use of vaginal pessary is another option, but the evidence is still limited. Surgical 
approaches include transvaginal and transabdominal cervical cerclage [46].
6.2 Acquired anatomical factors
Acquired anatomical factors commonly associated with RPL include uterine 
fibroids, endometrial polyps, and uterine synechiae. They usually develop after 
puberty due to physical or hormonal stimuli and are present in about 12% of 
patients with RPL [47].
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6.2.1 Uterine fibroids
Fibroid is reported in 8,2% of women with RPL [48]. Submucosal fibroids 
deform the endometrial cavity, thus affecting implantation and embryonic devel-
opment [47]. Hysteroscopy is considered the gold standard for the diagnosis of 
submucosal fibroids, but this pathology can be identified through other imaging 
exams, such as ultrasound mapping [2]. The evaluation of the uterine cavity is 
strongly recommended for all women with RPL, since the removal of submucosal 
fibroids in infertile patients seems to reduce the chance of miscarriage [2, 49]. 
Regarding fibroids that do not distort the uterine cavity, there is no evidence 
indicating that myomectomy may reduce the chances of an abortion [2, 49].
6.2.2 Uterine polyps
There seems to be a higher prevalence of endometrial polyps in women with 
gestational loss (2.4%), but with no well-defined clinical importance [2, 47]. 
Hysteroscopy is considered the gold standard exam for the diagnosis and treatment 
of endometrial polyps but can also be identified through other imaging exams, such 
as ultrasound with color Doppler [2]. Although there is no evidence of the benefit of 
polypectomy in women with RPL, hysteroscopic removal should be considered when 
the polyp is larger than 1 cm when no other known etiology is found [2, 47]. ASRM 
reports that research for uterine polyps in women with gestational loss is contro-
versial as there is no conclusive evidence that surgical treatment reduces the risk of 
gestational loss [49].
6.2.3 Uterine synechiae/Asherman syndrome
The prevalence of uterine synechiae ranges from 0.5 to 28% in patients with 
RPL [47]. Women with RPL are more likely to have uterine synechiae as they often 
undergo curettage or manual vacuum aspiration. The probable pathophysiology 
of abortion occurs due to a reduction in the amount of functional endometrium 
which may interfere with the invasion and normal development of the placenta 
[47]. The gold standard exam for the diagnosis of synechiae is hysteroscopy and 
should be the exam of choice in the cases of suspicion [2]. ESHRE concludes that 
there is insufficient evidence to recommend adhesiolysis in women with RPL as 
there are only small observational studies. ESHRE reinforces that treatment should 
focus on preventing recurrence of adhesions [2, 3]. However, ASRM points out that 
surgical correction of significant uterine cavity defects should be considered [3]. 
Nonsurgical experimental techniques for the treatment of uterine synechiae and 
endometrial fibrosis, such as stem cell therapy, should be further studied before 
being indicated in clinical practice [2].
7. Endocrine factors
Hormones play a key role in placentation, and their changes may result in the 
risk of miscarriage [2].
7.1 Luteal phase insufficiency
It is a condition of insufficient exposure to progesterone to maintain a secretory 
endometrium that will lead to normal embryo implantation and growth [50]. The 
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diagnostic criteria for luteal insufficiency are not well established which makes it 
difficult to conduct studies that can demonstrate the causal link between luteal phase 
insufficiency and RPL. Thus, luteal phase failure testing is not recommended for 
patients with RPL [2, 3]. The use of progesterone or human chorionic gonadotropin 
(hCG) for its treatment is divergent in the literature [2, 3].
7.2 Thyroid disorders
Studies relating subclinical hypothyroidism, defined as thyroid-stimulating 
hormone (TSH) > 2.5 mU/L and normal free thyroxine, and increased risk of RPL, 
have low levels of evidence [2]. The anti-thyroid peroxidase antibodies’ (anti-TPO) 
presence in patients with RPL, even euthyroid, is an important gestational prognos-
tic factor [51]. Thus, a TSH and anti-TPO dosage is recommended for women with 
RPL. And, in detecting abnormal levels of the above exams, it recommends that T4 
levels should be evaluated [2].
Patients with clinical hypothyroidism should be treated with levothyroxine [2, 3]. 
In women with RPL and subclinical hypothyroidism, the benefit of treatment should 
be evaluated as the evidences are conflicting [2, 3]. In addition, euthyroid women 
with positive anti-TPO should not be treated with levothyroxine [2, 52].
7.3 Polycystic ovary syndrome and disorders of insulin metabolism
Several abnormalities observed in patients with polycystic ovary syndrome 
(PCOS) have been independently associated with RPL, including insulin resistance, 
hyperinsulinemia, hyperandrogenemia, hyperprolactinemia, and obesity.
There is a higher prevalence of insulin resistance among women with RPL 
than controls [53]. However, no study has confirmed the cause-effect relationship 
between insulin resistance and RPL. Thus, there is insufficient evidence to recom-
mend assessment of PCOS, fast insulin and fast glucose, and insulin and glycemia 
nor the use of metformin in pregnancy to prevent gestational loss in women with 
RPL and defects in glucose metabolism [2].
The presence of an independent link between hyperandrogenemia and RPL 
remains controversial. Therefore, researching androgen levels is not recommended 
in women with RPL [2].
7.4 Prolactin disorders
Most studies fail to establish a direct link between RPL and serum prolactin 
concentration. Thus, prolactin test is not routinely recommended in the absence 
of clinical signs of hyperprolactinemia [2]. But if hyperprolactinemia is detected, 
treatment with dopaminergic agonists may be considered in women to increase live 
birth rates [2, 3].Since hyperprolactinemia is an easily treatable cause, most centers 
routinely test serum prolactin levels.
7.5 Vitamin D
There are few studies evaluating the association between vitamin D deficiency 
and RPL [2]. One of them showed increased prevalence of hypovitaminosis D in 
women with RPL, but it was unable to demonstrate cause-effect relationship [2, 
54]. Thus, based on the significant prevalence of hypovitaminosis D in women 
with RPL and possible association with obstetric and fetal complications, the 
preconception counseling in these women may include prophylactic vitamin D 
supplementation [2].
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8. Chronic endometritis
Chronic endometritis (CE) is defined as a persistent inflammation of the endo-
metrial mucosa caused by the presence of bacterial pathogens in the uterine cavity 
[55]. Its prevalence in patients with RPL is approximately 12–13% [56]. The influence 
of CE on reproductive capacity is controversial, but many authors suggest that CE 
may negatively affect embryonic implantation [56]. Some studies suggest an infec-
tious etiology with positive cultures in 75% of women with histologically confirmed 
CE, with the most common bacteria being Escherichia coli, Enterococcus faecalis, and 
Streptococcus agalactiae (77.5%) [57]. Most patients are asymptomatic, with pain on 
uterine or cervical mobilization being the most common clinical presentation [58, 59].
CE is histopathologically diagnosed as a lymphoplasmacytic infiltrate in the 
endometrial stroma [58, 59]. Immunohistochemistry for the marker present in CD138 
plasma cells is used to improve diagnostic accuracy [60]. A diagnostic video hysteros-
copy can help identify CE, with direct visualization of the endometrial cavity, which 
usually presents with mucosal edema, focal or diffuse endometrial hyperemia, or 
micropolyps. The sensitivity, specificity, and positive and negative predictive values of 
hysteroscopy in diagnosing CE were 86.36, 87.30, 70.37, and 94.82%, respectively [61].
Up to a few years ago, the uterine cavity was thought of as a sterile environment. 
Recently, there has been discussed that an imbalance of the uterine microbiota might 
compromise embryonic implantation or induce an abortion. Endometrial biopsy 
for next-generation sequencing (NGS) microbiota evaluation and etiological agent 
research can now be done through commercial kits [55]. However, further studies are 
needed to evaluate diagnostic efficacy and therapy on the reproductive outcomes.
Some studies suggest that treatment is related to increased live birth rates and 
reduced abortion rates [62]. There are several therapeutic options; the main ones 
mentioned in the literature refer to the use of doxycycline alone (100 mg, 12/12 hours 
orally, for 14 days) or the combination of metronidazole (250 mg, 12/12 hours orally, 
for 14 days) and ciprofloxacin (250 mg orally 12/12 hours for 14 days) [59].
9. Male factors
There is a growing acceptance of male etiological factors for RPL. Its screen-
ing consists of detailed sperm analysis. Excessive sperm DNA fragmentation is an 
important constraint to conception. Two meta-analyses have shown the association 
of gestational losses with high rates of sperm DNA fragmentation [63, 64]. The avail-
able tests for sperm DNA fragmentation index are the sperm chromatin structure 
assay (SCSA), the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick 
end labeling (TUNEL), the Sperm Chromatin Dispersion test, and the comet assay.
Some clinical conditions are related to increased fragmentation of sperm 
DNA. High seminal plasma leukocyte concentration, systemic infections, varicocele, 
and smoking, among others, were related to spermatic DNA damage [65]. A Cochrane 
meta-analysis suggests that the use of antioxidants, including vitamins C and E, 
may have benefits for subfertile men with no apparent cause, improving sperm DNA 
fragmentation [66]. The generally recommended dose is 1 gram of vitamin C and 
1000 IU of vitamin E per day for at least 2 months [67]. However, this effect is not yet 
established in patients with RPL. ESHRE determines that sperm DNA fragmentation 
research should be considered for explanatory purposes for RPL [2].
For intracytoplasmic sperm injection (ICSI)-indicated couples, laboratory 
techniques may be performed to select sperm with lower DNA fragmentation rate, 
such as physiological intracytoplasmic sperm injection (PICSI) and intracytoplas-
mic morphologically selected injection (IMSI). However, the use of testicular sperm 
Innovations in Assisted Reproduction Technology
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seems to improve fertilization, pregnancy, and live birth rates when compared to 
PICS and IMSI techniques [68]. Nevertheless, further studies are needed to identify 
the best method for selecting sperm to reduce abortion rates.
The morphological analysis of sperm is another point to consider in cases of 
RPL. The presence of spermatozoa with structural anomalies may be associated 
with aneuploidy, resulting in aneuploid embryos that usually do not implant or are 
aborted. This is especially true in cases of globozoospermia and macrospermia, 
forms of monomorphic teratospermia—when all sperms have the same anomaly 
[69]. Infertility is generally associated with these cases, and the prognosis of IVF is 
reserved. Thus, when associated with abortion, IVF followed by embryonic biopsy 
for preimplantation genetic testing for aneuploidies (PGT-A) may be an option.
10. Conclusion
Recurrent spontaneous abortion is an entity with a multifactorial etiology, 
and in approximately 50% of cases, we did not identify the cause of the loss. This 
explains the large number of controversies regarding the investigation and treat-
ment of the pathologies that lead to repeated losses.
Despite so much controversy, there are some points on which experts agree. 
Psychological support for couples is essential and is associated with a better progno-
sis in subsequent pregnancy. Undergoing through periodic consultations and ultra-
sounds especially during the period of previous losses reduces the stress of these 
couples. The woman’s age and number of previous losses are the most important 
factors in predicting the couple’s chance of having a live baby in the next pregnancy.
There is a need for consensus among human reproduction societies on the tests that 
must be ordered and diagnostic criteria for all specialists to evaluate couples evenly. In 
this way, we will be able to evaluate the effectiveness of each available treatment, avoid-
ing further financial burns, emotional disorders, and iatrogenesis for these couples.
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